These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 30711878)

  • 1. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Variability of the MIR196A2 Gene as a Risk Factor in Primary-Progressive Multiple Sclerosis Development].
    Kiselev IS; Kulakova OG; Baulina NM; Bashinskaya VV; Popova EV; Boyko AN; Favorova OO
    Mol Biol (Mosk); 2019; 53(2):282-289. PubMed ID: 31099778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis.
    Koch MW; Ilnytskyy Y; Golubov A; Metz LM; Yong VW; Kovalchuk O
    Eur J Neurol; 2018 Apr; 25(4):651-658. PubMed ID: 29316044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of primary progressive multiple sclerosis.
    Cree BA
    Handb Clin Neurol; 2014; 122():211-30. PubMed ID: 24507520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
    Boppana S; Mindur JE; Balashov KE; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2013 Dec; 265(1-2):68-74. PubMed ID: 24200257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis.
    Goertsches R; Baranzini SE; Morcillo C; Nos C; Camiña M; Oksenberg JR; Montalban X; Comabella M
    Mult Scler; 2008 Apr; 14(3):412-4. PubMed ID: 18208870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
    Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
    Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis.
    Rodrigues DN; Paes RA; Vasconcelos CC; Landeira-Fernandez J; Alvarenga MP
    Arq Neuropsiquiatr; 2011 Aug; 69(4):590-5. PubMed ID: 21877025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of interleukin-4 receptor alpha chain variants in multiple sclerosis.
    Hackstein H; Bitsch A; Bohnert A; Hofmann H; Weber F; Ohly A; Linington C; Mäurer M; Poser S; Rieckmann P; Bein G
    J Neuroimmunol; 2001 Feb; 113(2):240-8. PubMed ID: 11164908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.
    Boylan MT; Crockard AD; McDonnell GV; Armstrong MA; Hawkins SA
    J Neurol Sci; 1999 Aug; 167(2):79-89. PubMed ID: 10521545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.